Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- TMDU, Tokyo Govt Join Hands for Open Innovation in Drug Discovery, Healthcare
July 18, 2019
- Virologist Expresses Concern over Spread of Resistant Flu Viruses to Xofluza
July 17, 2019
- Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
- NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
- Gynecologist Stresses Urgent Need to Resume HPV Vaccinations, Cites Age Disparity in Cervical Cancer Risk
July 10, 2019
- Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
- Univ. of Tokyo, 3H to Start Matching Program for Rare Disease R&D
May 21, 2019
- Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
May 17, 2019
- Treatment with Corticosteroids Strongly Recommended for Sclerosing Cholangitis: New Guidelines
May 9, 2019
- Risk of Relapse Will Be Challenge for CAR-T Cell Therapy: Immunologist
May 8, 2019
- Niigata Univ., Eisai Team Up to Develop Pancreatic Cancer Drug Using Highly Absorbed Peptide
May 7, 2019
- Revised Hypertension Treatment Guidelines Set Stricter Blood Pressure Reduction Target
April 23, 2019
- Xofluza Shouldn’t Be Used Alone for Hong Kong Flu: Specialist
April 8, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
- Discuss Biosimilar Pricing Separate from High-Cost Medical Expense Benefits: Prof.
March 20, 2019
- NCNP to Set Up New Council to Accelerate Clinical Development of Neuromuscular Disorder Treatments
March 18, 2019
- Feburic Prevents Cerebral, Cardiorenovascular Events: Japan Multicenter Study
March 13, 2019
- Investigators Calling Off Trials on First Hyperlactacidemia Drug with No Significant Improvement Shown
February 28, 2019
- Keio Researchers Start Studying ReQuip for ALS after iPS Screening
February 25, 2019
- Revised Hyperuricemia Treatment Guidelines Recommend Uric Acid Production Inhibitors to Prevent Kidney Function Decline
January 21, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…